• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vaxess Technologies lands $6m for microneedle vaccines

March 6, 2017 By Sarah Faulkner

Vaxess Technologies lands $6m for microneedle vaccinesVaxess Technologies said today that it won 2 grants from the Bill & Melinda Gates Foundation totalling up to $6 million for the development of inactivated polio and live attenuated measles rubella vaccines using the company’s Mimix sustained-release microneedle patch technology.

The company’s Mimix technology is designed for sustained, transdermal delivery of vaccines and inmmunotherapies, according to Vaxess. The company engineered biopolymer microneedles to encapsulate antigens for controlled, transdermal administration and claims that the technology enhances efficacy, simplifies dosing and improves product stability under harsh environmental conditions.

“Vaxess has teamed up with the Bill & Melinda Gates Foundation to develop an innovative technology that will contribute to eradication of polio and prevention of measles and rubella by increasing vaccine access,” Vaxess VP Livio Valenti said in prepared remarks. “Products developed with our Mimix sustained-release vaccine delivery system will have increased product efficacy and will not require refrigeration, facilitating vaccination in resource-poor settings.”

The 1st grant of $3 million is for the preclinical development and manufacturing of a thermostable inactivated polio microneedle patch and the 2nd $3 million grant is for the preclinical development of a resorbable microneedle patch for delivery of live attenuated measles rubella vaccine.

“The use of the Mimix sustained-release microneedle patch to combine doses and simplify administration has the potential to streamline global eradication efforts,” CEO Michael Schrader said. “Vaxess is honored to work with the Bill & Melinda Gates Foundation to advance these life-saving products to market.”

“Vaxess’s Mimix platform, enabled by the unique properties of silk-derived biopolymers, offers tunable dermal delivery of antigens to optimize immune response and improve product profiles,” VP of R&D Kathryn Kosuda added. “With support from the Bill & Melinda Gates Foundation, we are excited to demonstrate the flexibility and power of this platform to advance IPV and MR vaccines.”

Filed Under: Drug-Device Combinations, Featured, Research & Development, Wall Street Beat Tagged With: Vaxess Technologies

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS